OncoFirm™ Revolutionizing Early Cancer Diagnostics through Cutting-Edge Antigen Technology
Our rapid lateral flow assay technology provides quick insights within minutes for timely interventions.
Point-of-care Benefits
Deep, actionable insights while your patients are on-site…
- Laboratory Accuracy in your Hand.
- Healthcare Without Borders.
- From Clinic to Field—Precision Anywhere.
- Cost-Efficiency & Scalability.
- High Performance.
- Low Overhead.
- Breakthrough Accuracy
- Scalable Science with Real-World Impact.
OncoFirm Diagnostics Corp. (a registered Delaware Corporation) for the development of Early Cancer Rapid Tests, we are in a premarket investment phase. Our mission will be in revolutionizing early rapid cancer diagnostics through cutting-edge Antigen Patents, Fluorescent Lateral Flow Tests (FLFTs) and traditional lateral flow assay (LFA) technology for rapid tests. Our proprietary rapid diagnostic solutions utilize various antigens, with highly specific biomarkers linked to cancer progression, to provide accurate, fast, and accessible screening tools. Available to hospitals, clinics, and diagnostic labs, cancer screening and progression programs, research in oncology and infectious diseases… Investor Disclaimer (1)
Advanced Antigen Technology for Superior Lateral Flow Cancer Screening
OncoFirm™ Revolutionizing Cancer Diagnostics through Cutting-Edge Technology
OncoFirm Diagnostics pioneers rapid cancer tests with advanced technology.
Accurate Testing
Ensure precise cancer diagnostics
Fast Results
Get fast and actionable results
Specialized Biomarkers
Leverage specific cancer biomarkers
Head of Investor Relations
OncoFirm™ Diagnostics | Location: Flexible (East Coast preferred) | Reports to: CEO About OncoFirm™ OncoFirm™ Diagnostics is redefining early cancer detection through proprietary, emotionally intelligent diagnostic platforms. We blend scientific…Application: Early Cancer Detection Using ccfDNA
Researchers applied MIGHT to liquid biopsy data, focusing on ccfDNA fragmentation patterns (e.g., fragment lengths, positions, and end motifs) to determine which features reliably indicate cancer: Challenge: False Positives Linked…17% ROI – Market Opportunity: Early Cancer Detection (MECD)
1. Explosive Global Growth 2. Clinical Need Meets Technological Promise 3. Regional Drivers and Adoption Summary Table Metric Value 2024 Global Market Size USD 1.0 – 1.24 billion 2030 Forecast…Role of Peanut Agglutinin in Cancer Detection
Peanut agglutinin (PNA) plays a role in cancer detection because it specifically binds to the Thomsen–Friedenreich antigen (T-antigen) — a carbohydrate structure that is hidden in normal cells but exposed…
